Randomized phase II trial of cetuximab with and without weekly paclitaxel in patients with previously treated advanced urothelial cancer

Trial Profile

Randomized phase II trial of cetuximab with and without weekly paclitaxel in patients with previously treated advanced urothelial cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Cetuximab (Primary) ; Paclitaxel (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Aug 2012 Status changed from active, no longer recruiting to completed, based on results reported in the Journal of Clinical Oncology.
    • 27 Aug 2012 Primary endpoint 'Progression-free-survival-duration' has been met.
    • 27 Aug 2012 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top